Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | FBP1 | P09467 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 2/20 | 0.32 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 4/20 | 0.31 |
| ▸ | NPC1 | O15118 | 3/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | LPL | P06858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20535309 | 0.79 | DPP4 (0.37) | KDM4EALDH1A1HPGDMAPTTAAR1 | |
| SCHEMBL2341397 | 0.77 | — | — | |
| SCHEMBL20550992 | 0.77 | FBP1 (0.36) | TDO2KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL2290788 | 0.77 | FBP1 (0.36) | TDO2KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL2177738 | 0.73 | — | — | |
| SCHEMBL8983864 | 0.73 | — | — | |
| SCHEMBL9190818 | 0.73 | ALDH1A1 (0.33) | TDO2KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL16613151 | 0.71 | RPS6KB2 (0.35) | TDO2KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL8914799 | 0.71 | RPS6KB2 (0.35) | KDM4EALDH1A1HPGDMAPTMEN1 | |
| SCHEMBL14958040 | 0.71 | RPS6KB2 (0.35) | KDM4EALDH1A1HPGDMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615659-B2 | Preparing a palladium(0) compound by the reaction of a palladium compound with a silicone containing compound in the presence of a base; palladium(0) compounds are suitable as homogeneous catalysts, or as precursors for preparing homogeneous catalysts; storage stability | UMICORE AG & CO. KG (DE) | 2009-11-10 | — | — | US | claimed |
| EP-1558621-B1 | METHODS FOR THE PREPARATION OF COMPOUNDS CONTAINING PALLADIUM (0) | UMICORE AG & CO KG (DE) | 2008-01-23 | — | — | EP | claimed |
| US-20060106239-A1 | Method for the production of compounds containing palladium(0) | UMICORE AG & CO. KG (DE) | 2006-05-18 | — | — | US | claimed |
| US-6686495-B2 | IN PRESENCE OF PALLADIUM CATALYST; USEFUL IN PRODUCING CHEMICAL INTERMEDIATES FOR PHARMACEUTICALS, OPTICAL BRIGHTENING AGENTS AND AGROCHEMICALS | OMG AG & CO KG (DE) | 2004-02-03 | — | — | US | claimed |
| US-20020107426-A1 | Process for the preparation of mono-, bi- or poly- functional biaryls | UMICORE AG & CO. KG (DE) | 2002-08-08 | — | — | US | claimed |
| EP-1199292-A1 | Process for the production of mono-, bi- or polyfunctional biaryls | OMG AG & Co. KG (DE) | 2002-04-24 | — | — | EP | claimed |
| US-20240116965-A1 | ORGANOMETALLIC COMPOUNDS | UMICORE AG & CO. KG (DE) | 2024-04-11 | — | — | US | disclosed |
| EP-4267591-A2 | ORGANOMETALLIC COMPOUNDS | Umicore AG & Co. KG (DE) | 2023-11-01 | — | — | EP | disclosed |
| US-20230125340-A1 | (POLY)THIOPHENE-(POLY)SILOXANE BLOCK COPOLYMER AND PRODUCTION METHOD THEREOF | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-04-27 | — | — | US | disclosed |
| WO-2022136049-A2 | ORGANOMETALLIC COMPOUNDS | UMICORE AG & CO. KG (DE) | 2022-06-30 | — | — | WO | disclosed |
| US-7615659-B2 | Preparing a palladium(0) compound by the reaction of a palladium compound with a silicone containing compound in the presence of a base; palladium(0) compounds are suitable as homogeneous catalysts, or as precursors for preparing homogeneous catalysts; storage stability | UMICORE AG & CO. KG (DE) | 2009-11-10 | — | — | US | disclosed |
| EP-1558621-B1 | METHODS FOR THE PREPARATION OF COMPOUNDS CONTAINING PALLADIUM (0) | UMICORE AG & CO KG (DE) | 2008-01-23 | — | — | EP | disclosed |
| US-20060106239-A1 | Method for the production of compounds containing palladium(0) | UMICORE AG & CO. KG (DE) | 2006-05-18 | — | — | US | disclosed |
| US-6686495-B2 | IN PRESENCE OF PALLADIUM CATALYST; USEFUL IN PRODUCING CHEMICAL INTERMEDIATES FOR PHARMACEUTICALS, OPTICAL BRIGHTENING AGENTS AND AGROCHEMICALS | OMG AG & CO KG (DE) | 2004-02-03 | — | — | US | disclosed |
| US-20020107426-A1 | Process for the preparation of mono-, bi- or poly- functional biaryls | UMICORE AG & CO. KG (DE) | 2002-08-08 | — | — | US | disclosed |
| EP-1199292-A1 | Process for the production of mono-, bi- or polyfunctional biaryls | OMG AG & Co. KG (DE) | 2002-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106239-A1 | Method for the production of compounds containing palladium(0) | RPS19, SCO2, MMS19 | TDO2 85/4885KDM4E 3552/4885ALDH1A1 3123/4885 |
| US-20240116965-A1 | ORGANOMETALLIC COMPOUNDS | DDT, PPOX, PDCD2L | TDO2 483/4885KDM4E 1447/4885ALDH1A1 2120/4885 |
| US-20020107426-A1 | Process for the preparation of mono-, bi- or poly- functional biaryls | CYP4F3, CYP4F2, CYP2F1 | TDO2 432/4885KDM4E 2972/4885ALDH1A1 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.